Market Closed -
Nasdaq
04:00:00 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
6.78
USD
|
+2.11%
|
|
+5.61%
|
-38.42%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,733
|
3,318
|
1,806
|
1,357
|
900
|
-
|
-
|
Enterprise Value (EV)
1 |
3,309
|
3,061
|
1,712
|
1,267
|
723.5
|
763.5
|
844.6
|
P/E ratio
|
-7.7
x
|
-8.04
x
|
-5.77
x
|
-3.95
x
|
-2.39
x
|
-2.37
x
|
-2.55
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
45.2
x
|
1,095
x
|
1,308
x
|
53.1
x
|
88.3
x
|
111
x
|
19.4
x
|
EV / Revenue
|
40
x
|
1,011
x
|
1,240
x
|
49.6
x
|
71
x
|
94.1
x
|
18.2
x
|
EV / EBITDA
|
-63.3
x
|
-8.55
x
|
-5.8
x
|
-3.45
x
|
-1.85
x
|
-1.96
x
|
-1.93
x
|
EV / FCF
|
-31.7
x
|
-39.3
x
|
-7.18
x
|
-4.16
x
|
-2.49
x
|
-2.49
x
|
-3.37
x
|
FCF Yield
|
-3.16%
|
-2.54%
|
-13.9%
|
-24%
|
-40.2%
|
-40.2%
|
-29.7%
|
Price to Book
|
4.9
x
|
3.7
x
|
1.76
x
|
1.79
x
|
1.25
x
|
-
|
-
|
Nbr of stocks (in thousands)
|
89,811
|
108,044
|
120,895
|
123,269
|
132,742
|
-
|
-
|
Reference price
2 |
41.56
|
30.71
|
14.94
|
11.01
|
6.780
|
6.780
|
6.780
|
Announcement Date
|
3/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
82.65
|
3.029
|
1.381
|
25.55
|
10.19
|
8.114
|
46.44
|
EBITDA
1 |
-52.25
|
-357.9
|
-295.1
|
-367.7
|
-390.4
|
-390.1
|
-437.9
|
EBIT
1 |
-55.8
|
-361.9
|
-299.3
|
-373
|
-401.1
|
-416.1
|
-413.6
|
Operating Margin
|
-67.51%
|
-11,946.58%
|
-21,670.89%
|
-1,460.11%
|
-3,934.67%
|
-5,128.93%
|
-890.61%
|
Earnings before Tax (EBT)
1 |
-52.41
|
-363.9
|
-290.5
|
-342
|
-375.6
|
-398.1
|
-399.7
|
Net income
1 |
-230.2
|
-363.9
|
-290.5
|
-342
|
-377.7
|
-402.6
|
-409.8
|
Net margin
|
-278.51%
|
-12,012.94%
|
-21,036.13%
|
-1,338.66%
|
-3,705.57%
|
-4,961.83%
|
-882.52%
|
EPS
2 |
-5.400
|
-3.820
|
-2.590
|
-2.790
|
-2.838
|
-2.861
|
-2.654
|
Free Cash Flow
1 |
-104.4
|
-77.88
|
-238.6
|
-304.4
|
-290.6
|
-306.6
|
-250.6
|
FCF margin
|
-126.33%
|
-2,571.05%
|
-17,273.86%
|
-1,191.74%
|
-2,850.96%
|
-3,778.88%
|
-539.62%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.567
|
0.419
|
0.365
|
0.344
|
0.253
|
0.226
|
0.119
|
25.2
|
-
|
10.01
|
0.1
|
0.1125
|
0.1
|
-
|
-
|
EBITDA
1 |
-65.85
|
-
|
-
|
-
|
-
|
-99.98
|
-104.7
|
-72.21
|
-90.82
|
-88.97
|
-98.27
|
-95.75
|
-93.16
|
-98.09
|
-100.5
|
EBIT
1 |
-66.89
|
-62.72
|
-77.81
|
-85.89
|
-72.85
|
-101.2
|
-106
|
-73.58
|
-92.2
|
-90.36
|
-102.6
|
-102.2
|
-101.9
|
-101.9
|
-104.3
|
Operating Margin
|
-11,796.65%
|
-14,969.21%
|
-21,318.08%
|
-24,968.6%
|
-28,794.86%
|
-44,768.58%
|
-89,117.65%
|
-291.95%
|
-
|
-903%
|
-102,609%
|
-90,846.52%
|
-101,920.33%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-67.46
|
-62.05
|
-76.79
|
-84.17
|
-67.5
|
-94.24
|
-98.5
|
-65.73
|
-83.5
|
-81.39
|
-96.01
|
-96.47
|
-96.99
|
-98.38
|
-100.3
|
Net income
1 |
-67.46
|
-62.05
|
-76.79
|
-84.17
|
-67.5
|
-94.24
|
-98.5
|
-65.73
|
-83.5
|
-81.39
|
-91.68
|
-98.53
|
-92.76
|
-100.3
|
-102.5
|
Net margin
|
-11,897%
|
-14,808.11%
|
-21,037.81%
|
-24,468.6%
|
-26,681.03%
|
-41,698.67%
|
-82,777.31%
|
-260.83%
|
-
|
-813.3%
|
-91,683.43%
|
-87,584.38%
|
-92,763.57%
|
-
|
-
|
EPS
2 |
-0.6200
|
-0.5700
|
-0.7100
|
-0.7600
|
-0.5600
|
-0.7800
|
-0.8100
|
-0.5400
|
-0.6700
|
-0.6200
|
-0.7347
|
-0.7282
|
-0.7244
|
-0.7000
|
-0.7133
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/8/23
|
11/2/23
|
2/22/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
423
|
257
|
94.1
|
90.3
|
176
|
137
|
55.4
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-104
|
-77.9
|
-239
|
-304
|
-291
|
-307
|
-251
|
ROE (net income / shareholders' equity)
|
-79%
|
-43.8%
|
-31.4%
|
-40.2%
|
-59.4%
|
-51%
|
-45.9%
|
ROA (Net income/ Total Assets)
|
-38.6%
|
-40.2%
|
-27.6%
|
-35.2%
|
-42.3%
|
-40%
|
-35.9%
|
Assets
1 |
596.4
|
904.1
|
1,054
|
971.9
|
892.4
|
1,006
|
1,141
|
Book Value Per Share
2 |
8.480
|
8.300
|
8.470
|
6.130
|
5.410
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-0.7800
|
-2.040
|
-2.450
|
-2.280
|
-1.920
|
-
|
Capex
1 |
1.93
|
3.47
|
9.06
|
4.13
|
6.02
|
5.14
|
5.17
|
Capex / Sales
|
2.34%
|
114.59%
|
656.19%
|
16.15%
|
59.09%
|
63.37%
|
11.14%
|
Announcement Date
|
3/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
6.78
USD Average target price
21.96
USD Spread / Average Target +223.95% Consensus |
1st Jan change
|
Capi.
|
---|
| -38.42% | 881M | | +41.79% | 50.93B | | -0.56% | 42.12B | | +49.62% | 42.05B | | -7.20% | 29.18B | | +12.59% | 26.02B | | -21.51% | 18.9B | | +6.92% | 13.21B | | +24.91% | 12.17B | | +29.60% | 12.16B |
Other Biotechnology & Medical Research
|